Copyright
©The Author(s) 2024.
World J Gastrointest Surg. Jun 27, 2024; 16(6): 1647-1659
Published online Jun 27, 2024. doi: 10.4240/wjgs.v16.i6.1647
Published online Jun 27, 2024. doi: 10.4240/wjgs.v16.i6.1647
Table 1 Baseline characteristics
Characteristics | Overall (771) | HTGP (241) | ABP (530) | P value | |
Age (yr) | 49 (37.0; 63.0) | 37 (26.0; 53.8) | 56 (30.0; 84.0) | < 0.001 | |
Sex, n (%) | < 0.001 | ||||
Male | 466 (60.4) | 184 (76.3) | 282 (53.2) | ||
Female | 305 (39.6) | 57 (23.7) | 248 (46.8) | ||
BMI (kg/m2) | 26 (23.4; 28.7) | 27.8 (22.0; 35.3) | 25.4 (19.0; 33.7) | < 0.001 | |
Smoking, n (%) | < 0.001 | ||||
N | 515 (66.8) | 131 (54.4) | 384 (72.5) | ||
Y | 256 (33.2) | 110 (45.6) | 146 (27.5) | ||
Drinking, n (%) | < 0.001 | ||||
N | 550 (71.3) | 147 (61) | 403 (76) | ||
Y | 221 (28.7) | 94 (39) | 127 (24) | ||
Diabetes, n (%) | < 0.001 | ||||
N | 643 (83.4) | 173 (71.8) | 470 (88.7) | ||
Y | 128 (16.6) | 68 (28.2) | 60 (11.3) | ||
Hypertension, n (%) | < 0.001 | ||||
N | 581 (75.4) | 202 (83.8) | 379 (71.5) | ||
Y | 190 (24.6) | 39 (16.2) | 151 (28.5) | ||
Hyperlipidemia, n (%) | < 0.001 | ||||
N | 583 (75.6) | 88 (36.5) | 495 (93.4) | ||
Y | 188 (24.4) | 153 (63.5) | 35 (6.6) | ||
Laboratory data | |||||
ALT | 63.6 (26.0; 181.3) | 31.9 (9.7; 111.7) | 108.8 (13; 616.8) | < 0.001 | |
AST | 46.2 (24.4; 130.2) | 28.8 (13.0; 114.1) | 70.1 (16.1; 638.0) | < 0.001 | |
ALP | 108.9 (79.1; 108.9) | 101.1 (41.9; 118.1) | 108.9 (55.3; 258.5) | < 0.001 | |
γ-GT | 219.5 (119.7; 219.5) | 219.5 (17.6; 318.2) | 219.5 (31.0; 696.6) | < 0.001 | |
ALB | 36.4 (31.8; 41.4) | 37.0 (21.6; 48.6) | 36.3 (18.3; 48.3) | 0.018 | |
TBIL | 23.7 (14.4; 36.7) | 19.9 (3.0; 44.4) | 27.1 (5.1; 106.1) | < 0.001 | |
DBIL | 8.8 (3.8; 13.4) | 4.0 (0.6; 15.1) | 11.2 (2.5; 67.2) | < 0.001 | |
TC | 4.8 (3.4; 5.4) | 6.8 (3.3; 17.7) | 4.0 (1.0; 5.5) | < 0.001 | |
TG | 1.9 (0.9; 3.9) | 7.4 (1.0; 38.8) | 1.1 (0.3; 3.9) | < 0.001 | |
SCr | 75.9 (62.9; 86.9) | 79.0 (43.4; 157.4) | 75.0 (48.4; 127.3) | 0.174 | |
AMY | 256.0 (82.6; 729.5) | 191.6 (30.0; 927.5) | 343.1 (38.4; 2053.5) | < 0.001 | |
LPS | 344.3 (97.7; 878.8) | 323.2 (47.5; 1312.0) | 391.9 (28.4; 1709.6) | 0.15 | |
PT-S | 12.8 (11.9; 13.3) | 12.2 (10.7; 14.4) | 12.9 (11.1; 16.0) | < 0.001 | |
FIB | 4.4 (3.3; 5.2) | 5.2 (2.6; 9.0) | 4.1 (2.4; 6.9) | < 0.001 | |
WBC | 11.1 (7.7; 14.5) | 11.8 (5.8; 21.0) | 10.6 (4.6; 20.2) | < 0.001 | |
Lym | 1.1 (0.7; 1.5) | 1.3 (0.7; 3.1) | 1.0 (0.4; 2.1) | < 0.001 | |
RBC | 4.6 (4.1; 5.1) | 5.0 (4.0; 6.1) | 4.4 (3.4; 5.7) | < 0.001 | |
RDW | 13.3 (12.5; 14.1) | 13.2 (9.8; 14.4) | 13.5 (9.9; 16.2) | 0.003 | |
PLT | 203.0 (164.0; 254.0) | 223.0 (134.1; 391.0) | 197.0 (103.6; 339.4) | < 0.001 | |
PDW | 16.8 (16.3; 17.4) | 17.3 (12.8; 19.1) | 16.6 (11.8; 18.1) | < 0.001 | |
NLR | 8.3 (4.5; 14.2) | 6.9 (1.6; 18.9) | 9.1 (2.1; 33.1) | < 0.001 | |
PLR | 184.3 (131.6; 273.6) | 160.5 (70.3; 379.0) | 203.1 (83.4; 518.6) | < 0.001 | |
Atlanta classification, n (%) | 0.001 | ||||
MAP | 437 (56.7) | 125 (51.9) | 312 (58.9) | ||
MSAP | 156 (20.2) | 40 (16.6) | 116 (21.9) | ||
SAP | 178 (23.1) | 76 (31.5) | 102 (19.2) | ||
Scoring systems | |||||
MCTSI | 4.0 (2.0; 6.0) | 4.0 (2.0; 8.0) | 4.0 (2.0; 8.0) | 0.005 | |
JSS | 1.0 (0; 2.0) | 1.0 (0; 4.0) | 1.0 (0; 4.0) | 0.029 | |
BISAP | 1.0 (0; 1.0) | 0 (0; 2.0) | 1.0 (0; 2.0) | < 0.001 | |
Modified Marshall | 2.0 (1.0; 4.0) | 2.0(0; 5.9) | 2.0 (0; 7.0) | 0.049 | |
SOFA | 1.0 (0; 3.0) | 1.0 (0; 4.0) | 1.0 (0; 5.0) | 0.163 | |
POF, n (%) | 0.247 | ||||
N | 537 (69.6) | 161 (66.8) | 376 (70.9) | ||
Y | 234 (30.4) | 80 (33.2) | 154 (29.1) | ||
SIRS, n (%) | 0.956 | ||||
N | 465 (60.3) | 145 (60.2) | 320 (60.4) | ||
Y | 306 (39.7) | 96 (39.8) | 210 (39.6) | ||
Hospital stay (d) | 13.5 (9.4; 19.2) | 12.0 (5.2; 29.3) | 14.3 (5.4; 36.1) | < 0.001 | |
Mortality, n (%) | 0.556 | ||||
N | 762 (98.8) | 239 (99.2) | 523 (98.7) | ||
Y | 9 (1.2) | 2 (0.8) | 7 (1.3) |
Table 2 Correlation analysis of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio with the acute pancreatitis Scoring System in hypertriglyceridemia-induced acute pancreatitis
Parameters | PLR | P value | NLR | P value |
Atlanta classification | 0.000 | 0.005 | ||
Mild/moderate | 152.1 (110.8; 198.0) | 6.3 (3.5; 10.2) | ||
Severe | 188.2 (137.9; 265.6) | 7.9 (5.5; 12.6) | ||
MCTSI | 0.087 | 0.235 | ||
< 4 | 150.6 (113.4; 197.4) | 6.1 (3.4; 10.1) | ||
≥ 4 | 161.7 (119.1; 240.6) | 7.0 (4.4; 11.2) | ||
JSS | 0.754 | 0.815 | ||
< 3 | 159.0 (119.9; 228.0) | 6.9 (3.9; 11.2) | ||
≥ 3 | 161.2 (108.2; 257.6) | 7.0 (5.0; 10.2) | ||
BISAP | 0.384 | 0.395 | ||
< 3 | 159.1 (119.0; 228.4) | 6.9 (4.0; 10.9) | ||
≥ 3 | 171.6 (136.7; 244.4) | 9.1 (5.8; 12.9) | ||
Modified Marshall | 0.167 | 0.813 | ||
< 2 | 156.2 (113.4; 214.1) | 6.8 (3.8; 11.6) | ||
≥ 2 | 165.1 (132.0; 239.1) | 7.0 (4.9; 10.3) | ||
SOFA | 0.011 | 0.005 | ||
< 3 | 155.6 (113.2; 214.9) | 6.4 (3.6; 10.1) | ||
≥ 3 | 175.0 (136.0; 259.6) | 8.0 (5.9; 12.8) |
Table 3 Correlation Analysis of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio with the acute pancreatitis Scoring System in acute biliary pancreatitis
Parameters | PLR | P value | NLR | P value |
Atlanta classification | 0.002 | 0.000 | ||
Mild/moderate | 194.0 (136.2; 286.2) | 8.1 (4.3; 13.8) | ||
Severe | 239.1 (171.0; 358.9) | 16.0 (8.9; 21.8) | ||
MCTSI | 0.021 | 0.000 | ||
< 4 | 190.8 (135.4; 268.6) | 7.4 (4.0; 12.8) | ||
≥ 4 | 212.7 (145.3; 322.9) | 11.2 (6.0; 17.6) | ||
JSS | 0.006 | 0.000 | ||
< 3 | 194.5 (139.2; 287.6) | 8.2 (4.3; 14.2) | ||
≥ 3 | 250.6 (150.7; 359.1) | 16.5 (8.7; 22.9) | ||
BISAP | 0.921 | 0.002 | ||
< 3 | 203.8 (141.9; 295.9) | 8.9 (4.5; 15.7) | ||
≥ 3 | 192.9 (130.4; 329.9) | 15.6 (11.2; 20.4) | ||
Modified Marshall | 0.015 | 0.000 | ||
< 2 | 181.2 (134.0; 272.3) | 6.0 (3.5; 12.0) | ||
≥ 2 | 217.2 (145.2; 314.6) | 11.3 (6.2; 18.3) | ||
SOFA | 0.555 | 0.000 | ||
< 3 | 198.5 (140.4; 296.4) | 8.2 (4.1; 14.5) | ||
≥ 3 | 212.2 (142.1; 311.3) | 12.4 (7.3; 19.3) |
Table 4 Predictive performance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and the acute pancreatitis Scoring System for the occurrence of persistent organ failure in hypertriglyceridemia-induced acute pancreatitis
Parameters | AUC | 95%CI | Sensitivity | Specificity | P value | |
Lower | Upper | |||||
MCTSI | 0.718 | 0.649 | 0.786 | 0.650 | 0.733 | < 0.001 |
JSS | 0.703 | 0.631 | 0.775 | 0.663 | 0.720 | < 0.001 |
BISAP | 0.705 | 0.634 | 0.775 | 0.725 | 0.652 | < 0.001 |
Modified Marshall | 0.772 | 0.708 | 0.835 | 0.663 | 0.795 | < 0.001 |
SOFA | 0.827 | 0.772 | 0.882 | 0.713 | 0.820 | < 0.001 |
PLR | 0.622 | 0.546 | 0.699 | 0.413 | 0.826 | 0.002 |
NLR | 0.619 | 0.546 | 0.693 | 0.800 | 0.720 | 0.003 |
Table 5 Predictive performance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and the acute pancreatitis Scoring System for the occurrence of persistent organ failure in acute biliary pancreatitis
Parameters | AUC | 95%CI | Sensitivity | Specificity | P value | |
Lower | Upper | |||||
MCTSI | 0.573 | 0.517 | 0.629 | 0.409 | 0.729 | 0.008 |
JSS | 0.760 | 0.715 | 0.805 | 0.591 | 0.782 | < 0.001 |
BISAP | 0.694 | 0.645 | 0.743 | 0.448 | 0.827 | < 0.001 |
Modified Marshall | 0.761 | 0.717 | 0.804 | 0.675 | 0.705 | < 0.001 |
SOFA | 0.746 | 0.703 | 0.789 | 0.942 | 0.465 | < 0.001 |
PLR | 0.569 | 0.516 | 0.621 | 0.727 | 0.418 | 0.013 |
NLR | 0.668 | 0.618 | 0.717 | 0.532 | 0.761 | < 0.001 |
- Citation: Xu MS, Xu JL, Gao X, Mo SJ, Xing JY, Liu JH, Tian YZ, Fu XF. Clinical study of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hypertriglyceridemia-induced acute pancreatitis and acute biliary pancreatitis with persistent organ failure. World J Gastrointest Surg 2024; 16(6): 1647-1659
- URL: https://www.wjgnet.com/1948-9366/full/v16/i6/1647.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v16.i6.1647